In the second phase of sepsis, the administration of adenosine antagonists and CD39/CD73 neutralizing antibodies could limit the immunosuppression, reducing the susceptibility to secondary infections and late metabolic and immune alterations (Figure 1). This evidence concerns the gene NT5E and Sepsis.